ArticleNature medicine2025
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Advancing antibody drug conjugates in gastrointestinal cancers.British journal of cancer · 2026Review
- A modular framework for antibody-drug conjugate biomarkers.Nature reviews. Clinical oncology · 2026Review
- Stage-Specific Mucin Reprogramming Across the Gastric Cancer Cascade: Unveiling Molecular Mechanisms and Novel Therapeutic Vulnerabilities.Biomolecules · 2026Review
- Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors.Journal of hematology & oncology · 2026Review
- Navigating Antibody-Drug Conjugate Sequencing in Gastric Cancer: Cross-Resistance Biology, Target Switching, and Decision-Making Frameworks for the Post-Progression Landscape.Current oncology reports · 2026Review
- Antibody-Drug Conjugates in the Treatment of Esophageal Cancer.Current treatment options in oncology · 2026Review
- Beyond Zolbetuximab: Next-Generation Targeting Strategies for CLDN18.2.Journal of gastrointestinal cancer · 2026Review
- Claudin 18.2 Targeting: A Pan-Cancer Perspective.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Article
- Claudin proteins as emerging therapeutic targets for solid tumours.Nature reviews. Cancer · 2026Review
- Translational advances in gastric cancer: integrating biomarkers, novel therapies, and microenvironment remodeling in 2025.Translational cancer research · 2026Review
- Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Review
- Clinicopathologic correlates of claudin 18.2 expression in esophagogastric cancer at multiple expression levels.ESMO gastrointestinal oncology · 2026Article
- CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing.Cancer management and research · 2026Review
- CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy.Frontiers in molecular medicine · 2026Review
- CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives.Journal of gastric cancer · 2026Review
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
- Single-cell atlas reveals a pro-metastatic RELB+ neutrophil-myeloid subset underlying lymph node metastasis in EGFR-wildtype LUAD.Frontiers in cell and developmental biology · 2026Article
- CLDN18.2-Targeted Therapy in Gastrointestinal Cancers.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Dan-Yun Ruan *Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.
Hao-Xiang Wu *Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.
Su-Xia Luo *Phase I Clinical Research Center, Henan Cancer Hospital, Zhengzhou, China.
Wen-Wen Huang *Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.
Xin-Jun LiangDepartment of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China.
Zuo-Xing NiuDepartment of Medical Oncology, Cancer Hospital of Shandong First Medical University, Ji'nan, China.
Qi DangPhase I Clinical Research Center, Cancer Hospital of Shandong First Medical University, Ji'nan, China.
Hong-Li LiDepartment of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Zhan-Yu PanDepartment of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Hong-Xia LuDepartment of Gastroenterology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
Yan-Qiao ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Xing-Ya LiDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiu-Ying XiaoDepartment of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shi-Rong CaiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yu-Gang DongPhase I Clinical Trial Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jian ZhangDepartment of Oncology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China.
Zhou LiDepartment of General Surgery, ZhuJiang Hospital of Southern Medical University, Guangzhou, China.
Hai-Tao LanDepartment of Medical Oncology, Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Chengdu, China.
Xin WangDepartment of Gastrointestinal Surgery, Peking University First Hospital, Beijing, China.
Ying ZhouDepartment of Pharmacy & Drug Clinical Trial Institution, Peking University First Hospital, Beijing, China.
Lian LiuDepartment of Medical Oncology, Qilu Hospital of Shandong University, Ji'nan, China.
He-Li LiuDepartment of Gastrointestinal Surgery, Xiangya Hospital Central South University, Changsha, China.
Ping-Sheng XuPhase I Clinical Trial Research Center, Xiangya Hospital Central South University, Changsha, China.
Ai-Li SuoDepartment of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Rui-Nuo JiaDepartment of Digestive Oncology, The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China.
Yong-Qiang LiDepartment of Digestive Oncology, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, China.
Xiao-Dong PengDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Si-Chen WangDepartment of Clinical Pharmacology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Ai-Ai YuDepartment of Biometrics, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Jie XieOncology Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Miao-Zhen QiuResearch Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. qiumzh@sysucc.org.cn.ORCID http://orcid.org/0000-0002-4774-6235
Rui-Hua XuResearch Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. xurh@sysucc.org.cn.ORCID http://orcid.org/0000-0001-9771-8534
Funding
No grant is acknowledged in the PubMed record.
Abstract
Claudin-18 isoform 2 (CLDN18.2), a tight junction protein expressed in non-malignant gastric epithelium and exposed on tumor cell surface during malignant transformation, is a promising therapeutic target for gastric and gastroesophageal junction (G/GEJ) cancers. SHR-A1904 is an antibody-drug conjugate comprising CLDN18.2-targeting monoclonal antibody, a DNA topoisomerase I inhibitor payload and a cleavable peptide-based linker. We conducted a first-in-human, three-stage, phase 1 study to evaluate SHR-A1904 in 95 previously treated patients with CLDN18.2-positive advanced G/GEJ cancer. In the dose-escalation stage (0.6-8.0 mg kg
Indexed as
Antibodies, MonoclonalClaudinsEsophageal NeoplasmsEsophagogastric JunctionImmunoconjugatesStomach NeoplasmsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedFemaleHumansMaleMaximum Tolerated DoseMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedClaudinsCLDN18 protein, humanImmunoconjugates
Identifiers
PMID
40670772What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.